Literature DB >> 7270572

Prevalence and pattern of drug treatment for behavior and seizure disorders of TMR students.

K D Gadow, J Kalachnik.   

Abstract

The prevalence and pattern of psychotropic and antiepileptic drug treatment for TMR children and adolescents in public schools were determined from teacher questionnaires and parent interviews. The relationship between drug use and age, race, and sex was also examined. The findings, indicated that during the school year, 10 percent of the students received medication for seizure disorders and 4.9 percent were treated for behavior disorders. An additional 1.8 percent were treated concurrently for both a seizure and a behavior disorder. The data also suggested that dosages of methylphenidate (Ritalin), the most frequently prescribed drug for persons with behavior disorders, were conservative. The results were interpreted with regard to drug use among nonretarded and severely and profoundly mentally retarded populations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7270572

Source DB:  PubMed          Journal:  Am J Ment Defic        ISSN: 0002-9351


  4 in total

1.  Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study.

Authors:  John A Tsiouris; Soh-Yule Kim; W Ted Brown; Jill Pettinger; Ira L Cohen
Journal:  J Autism Dev Disord       Date:  2013-03

2.  Long-term follow-up of children with mental retardation/borderline intellectual functioning and ADHD.

Authors:  B L Handen; J Janosky; S McAuliffe
Journal:  J Abnorm Child Psychol       Date:  1997-08

3.  Psychotropic drug treatment among learning-disabled, educable mentally retarded, and seriously emotionally disturbed students.

Authors:  D Cullinan; K D Gadow; M H Epstein
Journal:  J Abnorm Child Psychol       Date:  1987-12

Review 4.  Pharmacological treatment of self-injurious behavior in mentally retarded persons.

Authors:  N N Singh; C J Millichamp
Journal:  J Autism Dev Disord       Date:  1985-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.